×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GRTS – gritstone bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GRTS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/10
05:50 am
grts
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
High
Report
Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
10/3
05:57 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at B. Riley from a "strong-buy" rating to a "hold" rating.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at B. Riley from a "strong-buy" rating to a "hold" rating.
10/3
05:57 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
10/2
09:13 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.00 price target on the stock, down previously from $3.00.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.00 price target on the stock, down previously from $3.00.
10/1
02:02 pm
grts
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock, down previously from $4.00.
Medium
Report
Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock, down previously from $4.00.
10/1
07:36 am
grts
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
High
Report
Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
9/30
04:05 pm
grts
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
High
Report
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/16
04:06 pm
grts
Form 8-K Gritstone bio, Inc. For: Oct 11
High
Report
Form 8-K Gritstone bio, Inc. For: Oct 11
10/10
08:30 am
grts
Form 8-K Gritstone bio, Inc. For: Oct 10
High
Report
Form 8-K Gritstone bio, Inc. For: Oct 10
10/7
05:01 pm
grts
Form SC 13G Gritstone bio, Inc. Filed by: RedCo II Master Fund, L.P.
Medium
Report
Form SC 13G Gritstone bio, Inc. Filed by: RedCo II Master Fund, L.P.
10/1
06:02 am
grts
Form 8-K Gritstone bio, Inc. For: Sep 30
High
Report
Form 8-K Gritstone bio, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/8
Gritstone Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference
15.2%
3/13 Gritstone Oncology Inc (NASDAQ: GRTS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.8%
4/6 Gritstone Oncology Announces the Appointment of Veteran Legal Executive Rahsaan Thompson as General Counsel 9.0%
4/7 Gritstone Oncology (GRTS) Investor Presentation - Slideshow [Seeking Alpha] 8.7%
2/14 Form SC 13G/A Gritstone Oncology, Inc. Filed by: Redmile Group, LLC 6.3%
10/31 Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference 5.9%
12/23 Hedge Funds Are Dumping Natural Resource Partners LP (NRP) [Yahoo! Finance News] 5.7%
1/17 Gritstone Oncology Inc (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at Cowen Inc. 4.5%
11/21 Form SC 13G Gritstone Oncology, Inc. Filed by: Casdin Capital, LLC 3.9%
6/20 Form 4 Gritstone Oncology, Inc. For: Jun 19 Filed by: Svennilson Peter 2.8%
3/13 Gritstone Oncology Inc (NASDAQ: GRTS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.8%
4/6 Gritstone Oncology Announces the Appointment of Veteran Legal Executive Rahsaan Thompson as General Counsel 9.0%
4/7 Gritstone Oncology (GRTS) Investor Presentation - Slideshow [Seeking Alpha] 8.7%
2/14 Form SC 13G/A Gritstone Oncology, Inc. Filed by: Redmile Group, LLC 6.3%
10/31 Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference 5.9%
12/23 Hedge Funds Are Dumping Natural Resource Partners LP (NRP) [Yahoo! Finance News] 5.7%
1/17 Gritstone Oncology Inc (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at Cowen Inc. 4.5%
11/21 Form SC 13G Gritstone Oncology, Inc. Filed by: Casdin Capital, LLC 3.9%
6/20 Form 4 Gritstone Oncology, Inc. For: Jun 19 Filed by: Svennilson Peter 2.8%
TOP News Decliners
12/13
Form 8-K Gritstone Oncology, Inc. For: Dec 12
-13.6%
3/11 Form S-8 Gritstone Oncology, Inc. -13.4%
2/22 Gritstone Oncology Inc (NASDAQ: GRTS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
12/12 Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE -11.4%
5/1 Gritstone Oncology Announces the Appointment of Dr. Elaine V. Jones as Chair of the Board of Directors -10.0%
6/24 Form 8-K Gritstone Oncology, Inc. For: Jun 19 -9.5%
3/14 Gritstone Oncology Inc (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. -8.7%
9/12 Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones -6.8%
2/7 Form SC 13G/A Gritstone Oncology, Inc. Filed by: FMR LLC -6.0%
11/26 Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference -5.5%
3/11 Form S-8 Gritstone Oncology, Inc. -13.4%
2/22 Gritstone Oncology Inc (NASDAQ: GRTS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -12.1%
12/12 Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE -11.4%
5/1 Gritstone Oncology Announces the Appointment of Dr. Elaine V. Jones as Chair of the Board of Directors -10.0%
6/24 Form 8-K Gritstone Oncology, Inc. For: Jun 19 -9.5%
3/14 Gritstone Oncology Inc (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. -8.7%
9/12 Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones -6.8%
2/7 Form SC 13G/A Gritstone Oncology, Inc. Filed by: FMR LLC -6.0%
11/26 Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference -5.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: